FibroScan檢測2266例慢性乙型肝炎脂肪肝/肝纖維化

StephenW

FibroScan Detection of Fatty Liver/Liver Fibrosis in 2266 Cases of Chronic Hepatitis B
Tingshan He  1 , Jing Li  1 , Yanling Ouyang  1 , Guotao Lv  1 , Xiaofeng Ceng  2 , Zhiqiao Zhang  1 , Jianqiang Ding  1
Affiliations
Affiliations

    1
    Department of Infectious Diseases, Shunde Hospital, Southern Medical University, Shunde, Guangdong, China.
    2
    Department of Pathology, Shunde Hospital, Southern Medical University, Shunde, Guangdong, China.

    PMID: 32832390 PMCID: PMC7438355 DOI: 10.14218/JCTH.2019.00053

Abstract

Background and Aims: FibroScan is used to determine liver stiffness and controlled attenuation parameter (referred to as CAP) scores in patients, including those with chronic hepatitis B (CHB). We used FibroScan to detect the incidence of fatty liver and fibrosis in CHB patients, and to assess the correlation of FibroScan measurements with blood chemistry tests. Methods: CHB patients enrolled in this study were divided independently for three separate analyses (of fibrosis, cirrhosis, and fatty liver) based on FibroScan results. Basic information, blood chemistry test results, liver fibrosis parameters, and FibroScan results were collected. T-tests and Pearson's analyses were used to analyze the correlations between FibroScan liver stiffness measurement/CAP values and liver function, blood fat, uric acid metabolite, fibrosis, and hepatitis B virus load. Results: A total of 2266 CHB patients were enrolled in the study and divided into three groups: non-significant and significant fibrosis; non-cirrhosis and early cirrhosis; and non-fatty and fatty liver. Spearman's statistical analyses showed that liver stiffness measurement or CAP values correlated with sex (r=0.137), age (r=0.119),glutamic-pyruvic transaminase (r=0.082), glutamic-oxaloacetic transaminase (r=-0.172), gamma-glutamyltransferase (r=0.225), albumin (r=0.150), globulin (r=-0.107), total bilirubin (r=-0.132), direct bilirubin (r=-0.145), white blood cell count (r=0.254), hemoglobin (r=0.205), platelets (r=0.206), total cholesterol (r=0.214), high density lipoprotein (r=-0.243), low density lipoprotein (r=0.255), apolipoprotein B (r=0.217), hyaluronic acid (r=-0.069), laminin (r=-0.188), procollagen type IV (r=-0.067)and hepatitis B viral DNA load (r=-0.216). Conclusions: FibroScan is a non-invasive device that can detect the occurrence of fatty liver or liver fibrosis in CHB patients.

Keywords: Chronic hepatitis B; Cirrhosis; Fatty liver; FibroScan; Liver fibrosis.

© 2020 Authors.
Conflict of interest statement

The authors have no conflict of interests related to this publication.

StephenW

FibroScan檢測2266例慢性乙型肝炎脂肪肝/肝纖維化
何廷山1，李莉1，歐陽陵1，呂國濤1，曾曉峰2，張志喬1，丁建強1
隸屬關係
隸屬關係

    1個
    南方醫科大學附屬順德醫院感染科，廣東順德。
    2
    南方醫科大學順德醫院病理科，廣東順德

    PMID：32832390 PMCID：PMC7438355 DOI：10.14218 / JCTH.2019.00053

抽象

背景和目的：FibroScan用於確定患者（包括患有慢性乙型肝炎（CHB）的患者）的肝硬度和受控衰減參數（稱為CAP）評分。我們使用FibroScan檢測CHB患者脂肪肝和纖維化的發生率，並評估FibroScan測量值與血液化學測試的相關性。方法：根據FibroScan結果，將參與該研究的CHB患者獨立分為三個獨立的分析（纖維化，肝硬化和脂肪肝）。收集了基本信息，血液化學測試結果，肝纖維化參數和FibroScan結果。使用T檢驗和Pearson分析來分析FibroScan肝硬度測量值/ CAP值與肝功能，血脂，尿酸代謝產物，纖維化和乙肝病毒載量之間的相關性。結果：總共2266名CHB患者被納入研究，分為三組：非顯著纖維化和顯著纖維化。非肝硬化和早期肝硬化；以及非脂肪肝和脂肪肝。 Spearman的統計分析表明，肝硬度測量值或CAP值與性別（r = 0.137），年齡（r = 0.119），谷氨酸-丙酮酸轉氨酶（r = 0.082），谷氨酸-草酰乙酸轉氨酶（r = -0.172），γ-谷氨酰轉移酶（r = 0.225），白蛋白（r = 0.150），球蛋白（r = -0.107），總膽紅素（r = -0.132），直接膽紅素（r = -0.145），白細胞計數（r = 0.254），血紅蛋白（r = 0.205），血小板（r = 0.206），總膽固醇（r = 0.214），高密度脂蛋白（r = -0.243），低密度脂蛋白（r = 0.255），載脂蛋白B（r = 0.217），透明質酸酸（r = -0.069），層粘連蛋白（r = -0.188），IV型膠原蛋白（r = -0.067）和乙型肝炎病毒DNA載量（r = -0.216）。結論：FibroScan是一種非侵入性設備，可以檢測CHB患者脂肪肝或肝纖維化的發生。

關鍵字：慢性乙型肝炎；肝硬化；脂肪肝;纖維掃描肝纖維化。

©2020作者。
利益衝突聲明

作者與本出版物無利益衝突。

StephenW

http://publine.xiahepublishing.c ... JCTH.2019.00053.pdf